DSG's EDC to be Used by Biotech Co. for Chronic Kidney Disease
MALVERN, Pa., Jan. 29, 2010 —DSG‘s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current Phase II and Phase IIa clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG’s eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.
The Phase II study, is a new treatment that may help people in the early stage of diabetic nephropathy, a progressive kidney disease. The second study, currently in Phase IIa, is a treatment for anemia in chronic kidney disease. The two clinical trials demand a data capture and management solution that speeds time-to-market while complying with all appropriate regulatory procedures. “Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG’s unique eCaseLink™ EDC system to be employed in clinical trials,” said Tony Varano, CEO of DSG.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
